Clinical Significance of Serum Vascular Endothelial Growth Factor in Malignant Pleural Mesothelioma

• DOI: 10.1097/jto.0b013e3181d2f008
• Publication Date: 2010-03-19T04:52:13Z
• Authors: Akihiro Yasumitsu; Chiharu Tabata; Rie Tabata; Noriko Hirayama; Aki Murakami; Shusai Yamada; Takayuki Terada; Shinichiro Iida; Kunihiro Tamura; Kazuya Fukuoka; Kozo Kuribayashi; Takashi Nakano
• Keywords: Pulmonary and Respiratory Medicine; Male; Mesothelioma; Vascular Endothelial Growth Factor A; Pleural Neoplasms; Asbestos; Enzyme-Linked Immunosorbent Assay; Prognosis; 3. Good health; Survival Rate; 03 medical and health sciences; 0302 clinical medicine; Oncology; ROC Curve; Occupational Exposure; Asbestosis; Biomarkers, Tumor; Humans; Tumor marker; Female; Cytokine; Aged; Neoplasm Staging

Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin associated with asbestos exposure. MPM has a limited response to conventional chemotherapy and radiotherapy so diagnosing MPM early is very important. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for MPM. Here, we investigated the serum levels of VEGF in patients with MPM in comparison with a population that had been exposed to asbestos without developing MPM.Serum concentrations of VEGF were measured in 51 patients with MPM and 42 individuals with benign asbestos-related diseases (asbestosis or pleural plaques) or who were healthy despite asbestos exposure.We demonstrated that patients with MPM had significantly higher serum levels of VEGF than a population who had been exposed to asbestos but had not developed MPM, and the patients with advanced stage MPM showed higher levels of VEGF than the early stage patients with MPM. The difference in overall survival between the groups with VEGF serum levels lower and higher than the assumed cutoff of 460 pg/ml was significant.Our data suggest that the VEGF serum concentration could be a useful marker for screening MPM among asbestos-exposed individuals and as a prognostic factor.